Opinion
Video
Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian
Author(s):
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Today-
We are reporting from the 2023 ESMO Congress!
Get ready for highlights of some of the top news presented each day during the meeting—and soon we’ll speak with Dr Ignace Vergote to discuss some new data in gynecologic cancer, Dr Yelena Janjigian to highlight exciting developments in gastrointestinal cancer, Dr Jacob Sands to share key advances in lung cancer, and Drs Paolo Tarantino and Aditya Bardia to provide perspective on practice-changing data in breast cancer.
Welcome to OncLive News Network! I’m Caroline Seymour.
Findings from the phase 3 TROPION-Lung01 trial (NCT04656652) showed that the TROP-2-directed antibody-drug conjugate datopotamab deruxtecan produced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs docetaxel in pretreated patients with advanced or metastatic non–small cell lung cancer (NSCLC) with or without actionable genomic alterations. Notably, longer median PFS was reported in the subgroup of patients with nonsquamous histology.
Moreover, datopotamab deruxtecan produced a statistically significant and clinically meaningful improvement in PFS vs investigator’s choice chemotherapy in patients with inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer following 1 to 2 prior lines of chemotherapy in the phase 3 TROPION-Breast01 trial (NCT05104866).
In the phase 3 innovaTV 301 trial (NCT04697628), tisotumab vedotin-tftv (Tivdak) led to a 30% reduction in the risk of death vs investigator’s choice of chemotherapy as second- or third-line therapy in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy. The results showed that at a median follow-up of 10.8 months (95% CI, 10.3-11.6), the median overall survival (OS) was 11.5 months (95% CI, 9.8-14.9) with tisotumab vedotin vs 9.5 months (95% CI, 7.9-10.7) with chemotherapy.
Finally, in results from the phase 3 RUBY trial (NCT03981796), the addition of dostarlimab-gxly (Jemperli) to carboplatin and paclitaxel was associated with improved PFS and OS in subgroups of patients with mismatch repair–deficient and microsatellite instability–high disease, patients with no specific molecular profile, and those with TP53 mutations, providing prognostic value in primary advanced or recurrent endometrial cancer.
Please be sure to check out more of our coverage from the 2023 ESMO Congress at OncLive.com.
That’s all for today.
Thank you for watching OncLive News Network: On Location, I’m Caroline Seymour.
